Slide 1: Shaping the future now
FY23 Full Year Results | ASX:MDR Shaping the future now 7 September 2023
Slide 2: Important notice and disclaimer
Important notice and disclaimer This presentation provides general information about completeness of the information or for any of the opinions regulatory requirements. This presentation does not constitute MedAdvisor Solutions which is current at the date this contained herein or for any errors, om
Slide 3: Agenda
Agenda 1 Doing what we said we would do 2 Driving solid financial results 3 Delivering real progress in ANZ1 and US 4 A new company emerges Rick Ratliff Ancila Desai CEO & Managing Director Global Chief Financial Officer 5 Shaping the future and Company Secretary 6 FY24 outlook 7 Q&A 1 ANZ – Austral
Slide 4: Our future is in our hands, as we work to achieve enduring profitable growth
“ Our future is in our hands, as we work to achieve enduring profitable growth. Our singular purpose is to deliver innovative, data-driven, omni-channel personalised solutions intended to simplify people’s medication journey and empower the pharmacy of the future. ” Rick Ratliff CEO & Managing Direc
Slide 5: Doing what we said we would do
Doing what we said we would do 5 FY2023 Investor Presentation: Shaping the future now
Slide 6: Positioned for profitability in FY24
Positioned for profitability in FY24 In FY23, our Pathway to Profitability initiative fortified our global platform, improved our cost base, and sparked the engine for sustained profitable growth. Global platform Business operations Product innovation • Migration of 1,414 GuildLink pharmacies to • I
Slide 7: Driving solid financial results
Driving solid financial results 7 FY2023 Investor Presentation: Shaping the future now
Slide 8: FY23 group highlights – overall business
FY23 group highlights – overall business Continued momentum on our Pathway to Profitability. FY23 revenue of FY23 gross margin of $98.0M up 44.6% YOY 60.6% up $24.5M YOY EBITDA of ($3.0M) improved by Strong cash position of $8.3M+ All financials are in AUD, unless stated otherwise. $14.2M 8 FY2023 I
Slide 9: Revenue showing strong momentum YOY
Progressing towards profitability Revenue Group operating revenue (In millions AUD) showing strong US ANZ $98.0M momentum YOY. MedAdvisor Solutions delivered strong financial results in FY23, with group level revenue of $98.0 million, $67.8M representing a 44.6% increase over FY22, supported by grow
Slide 10: Gross profit showing strong momentum YOY
Progressing towards profitability Gross profit showing Change of Gross profit (In millions AUD) strong momentum YOY. 69.7% from FY22 Gross profit rose by 69.7% to $59.4 million and gross margin improved by 9.0 percentage points to 60.6%, driven by shift in product mix to digital medication awareness
Slide 11: EBITDA improvement driving towards profitability in FY24
Progressing towards profitability EBITDA improvement driving towards EBITDA (In millions AUD) ONE-TIME OR NON-RECURRING COSTS profitability in FY24. $24.5M Revenue and margin uplift: Improvement due to shift in product mix to digital medication awareness and adherence programs. Performance-based rem
Slide 12: Reported cash flow = strong cash position
Progressing towards profitability Reported cash flow = strong cash position. Cash flow (In millions AUD) $29.5M Net receipts and payments: Strong customer receipt growth from both the US and AU, and disciplined working capital management. Net cash acquired from acquisition: Net cash $14.2M acquired
Slide 13: Delivering real progress in ANZ and US
Delivering real progress in ANZ and US 13 FY2023 Investor Presentation: Shaping the future now
Slide 14: FY23 highlights—ANZ
FY23 highlights—ANZ In ANZ, we achieved strong YOY growth as the pharmacy network expanded through acquisition and partnering. FY23 revenue (including GuildLink acquisition) of GuildLink integration completed on time and under budget, adding 1,414 Serving over 95% 95% $19.9M of Australian pharmacies
Slide 15: Case study: Supporting a Urinary Tract Infection (UTI) initiative in Australia
Case study: Supporting a Uninary Tract Infection (UTI) initiative in Australia MedAdvisor Solution’s Plus One software supports an extended scope of practice for Australian pharmacists with a UTI recording form. In 2020, the state of Queensland launched In 2023, the state of New South Wales undertoo
Slide 16: FY23 highlights—US
FY23 highlights—US In the US, we achieved strong YOY growth as a seasonal business, with bulk of revenue booked in the first half of each financial year. FY23 revenue of We continued to expand our pharmacy network $78.1M and patient reach across the US. 32K up 45.5% YOY US pharmacy network expanded
Slide 17: FY23 market impact highlights—US pharma-sponsored programs
FY23 market impact highlights—US pharma-sponsored programs Our pharma-sponsored Therapeutic categories for pharma-sponsored programs in the US (Non-vaccine as a percentage of total FY23 programs) programs continued to ADHD 5% Cholesterol deliver value to patients. Other 2% 14% Depression 1% Vaccine
Slide 18: Case study: THRiV delivers for a Fortune life sciences client
Case study: THRiV™ delivers for a Fortune 500 life sciences client MedAdvisor Solution’s THRiV™ omni-channel intelligent patient management platform solves for supporting new-to-brand patients. A leading life sciences brand in the cholesterol Results category was experiencing the following pain poin
Slide 19: A new company emerges
A new company emerges 19 FY2023 Investor Presentation: Shaping the future now
Slide 20: A different company from a year ago
A different company from a year ago Combining the best of MedAdvisor, Adheris Health, and GuildLink to create a global force in patient engagement and community pharmacy impact. Committed to a unified approach as “One MedAdvisor Solutions.” 20 FY2023 Investor Presentation: Shaping the future now
Slide 21: A purposeful rebrand
A purposeful rebrand In FY23, as MedAdvisor Solutions, we put all our people on the same page worldwide. Our Values Operate with integrity At our core, we believe in doing what’s right One Vision To inspire lasting even when no one is watching. behaviour change by simplifying Innovate with passion W
Slide 22: Our social responsibility journey
Our social responsibility journey We are proud to highlight our unwavering Diversity and MedAdvisor Solutions (% of women) commitment to delivering innovative patient engagement solutions while maintaining a keen awareness of our environmental, social, 33% 55% 52% and governance responsibility. Wome
Slide 23: Shaping the future
Shaping the future 23 FY2023 Investor Presentation: Shaping the future now
Slide 24: Growth drivers
Growth drivers The future we are building today is The Pharmacy of the Future aligned with and shaped by the essential drivers propelling our industry forward. • Driving vaccine and chronic medication awareness and adherence through the community pharmacy • Expansion of individualised patient medica
Slide 25: Our strategy going forward
Our strategy going forward Our initial 5-year strategy, developed in FY23, has identified a core set of initiatives with a total addressable market of over $20B. These initiatives will be steered by the following key drivers: • Increasing patient reach and engagement • Strengthening and expanding co
Slide 26: FY24 outlook
FY24 outlook 26 FY2023 Investor Presentation: Shaping the future now
Slide 27: Our immediate focus
Our immediate focus We seek sustained profitability, driving growth with efficiency and discipline as a unified global leader in personalised medication management. 1 Continuing rollout of our single global platform while enhancing functionality and “cloud-first” automation— 2 Optimising business op
Slide 28: Going into FY24 with strong momentum
Going into FY24 with strong momentum Given our strong performance in FY23, we expect continued growth in revenue and solid improvement in profitability in FY24. We will continue to build on key themes of vaccines, digitalisation, and helping to expand pharmacy scope of practice. Solid pipeline in US
Slide 29: Shaping the future now: Q&A
Shaping the future now: Q&A 29 FY2023 Investor Presentation: Shaping the future now